CNS Pharmaceuticals, Inc.

CNSPSEC EDGAR

Pharmaceutical Preparations(NV)CIK: 1729427

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$14.1M	$9.3M	$9.8M	$5.1M	$1.9M
Operating Expenses	$18.9M	$15.3M	$14.5M	$9.5M	$3.8M
Operating Income (Loss)	-$18.9M	-$15.3M	-$14.5M	-$9.5M	-$3.8M
Interest Expense	—	$7.0K	$9.3K	$3.3K	$26.2K
Nonoperating Income (Expense)	$13.9K	-$7.0K	-$9.3K	-$3.3K	-$44.2K
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$18.9M	-$15.3M	-$14.5M	-$9.5M	-$3.9M
Earnings Per Share, Basic	-$12.5K	-$11.22	-$16.50	—	—
Earnings Per Share, Diluted	-$12.5K	-$11.22	-$16.50	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$1.7M	$13.1M	$8.8M	$15.9M	$7.9M
Assets, Current	$1.6M	$12.6M	$7.5M	$15.5M	$7.9M
Cash and Cash Equivalents, at Carrying Value	$548.7K	$10.1M	$5.0M	$14.0M	$7.2M
Liabilities	$6.1M	$4.9M	$2.6M	$1.9M	$311.0K
Liabilities, Current	$6.1M	$4.9M	$2.6M	$1.9M	$311.0K
Accounts Payable, Current	—	—	$2.0M	$946.3K	$243.7K
Stockholders' Equity Attributable to Parent	$8.1M	$6.2M	$13.9M	$7.6M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$14.1M	-$10.6M	-$13.5M	-$7.3M	-$3.6M
Net Cash Provided by (Used in) Investing Activities	-$3.9K	-$4.4K	-$5.7K	-$17.9K	-$20.1K
Net Cash Provided by (Used in) Financing Activities	$4.6M	$15.6M	$4.5M	$14.1M	$10.3M
Payments to Acquire Property, Plant, and Equipment	$3.9K	$4.4K	$5.7K	—	$20.1K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)